Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scancell HoldingsSCNLF 21 Equity-to-Asset is -0.54 as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 1,416 Biotechnology companies, Scancell Holdings ranks worse than 91.45% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Scancell Holdings Equity-to-Asset Related Terms
Scancell Holdings Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Scancell Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCNLF vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Scancell Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scancell Holdings Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scancell Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Scancell Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Scancell Holdings's Equity to Asset Ratio for the fiscal year that ended in Apr. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scancell Holdings (SCNLF) has a Equity-to-Asset of -0.54 as of Oct. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Scancell Holdings and its competitors. According to the industry distribution chart, Scancell Holdings ranks #1295 out of 1416 companies in the Biotechnology industry, placing it in the top 91.5%.
Is Scancell Holdings' Equity-to-Asset too high?
Scancell Holdings' current Equity-to-Asset is -0.54. Based on the distribution chart, Scancell Holdings ranks #1295 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Scancell Holdings has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #1295 out of 1416 companies for Equity-to-Asset. This places Scancell Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Scancell Holdings and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scancell Holdings's current Equity-to-Asset is -0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current Equity-to-Asset of -0.54. The current Equity-to-Asset is -0.54. Scancell Holdings' overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current Equity-to-Asset is -0.54 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
21GF Score
Get the complete analysis for SCNLF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNLF has been successfully added to your 
